FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2095470682> ?p ?o ?g. }

• W2095470682 endingPage "815" @default.
• W2095470682 startingPage "809" @default.
• W2095470682 abstract "Objective To study the effect of daily treatment with 50 mg of aspirin (ASA) on the hypertensive pregnancy complications and on the production prostacyclin (PGI2) and thromboxane A2 (TxA2) in high risk pregnant women and their infants. Design Placebo controlled prospective study. Setting Departments of Obstetrics and Gynaecology, University of Helsinki, University of Oulu and Central Hospital of Middle Finland, Finland. Subjects Two hundred and eight pregnant women with pre-existing hypertension or a history of severe preeclampsia in their previous pregnancy. Prostanoids were studied in a subgroup of 18 women. Interventions The women were randomised to receive ASA (50 mg/day, n= 103) or placebo (n= 105) from the mean of 15 weeks gestational age to delivery. The exacerbation of pre-existing hypertension or the appearance of hypertension in previously normotensive women, the appearance of proteinuria and fetal growth were the main end points, but some other clinical characteristics were also recorded. Urinary excretion of PGI2 and TxA2 metabolites by mothers and infants and their production in umbilical arteries in vitro were also studied. Results Two women (one in both groups) had miscarriages, and one pregnancy was terminated for fetal anencephaly (ASA group). In addition, seven women discontinued the treatment due to urticaria (two women in ASA group), increased activity of aspartate amino tranferase in serum (one woman in both groups), or increased bleeding time (one woman in ASA group, two women in placebo group), and one woman in the placebo group was lost from follow-up. Thus the end points could be assessed in 97 women taking ASA and 100 women taking placebo. ASA did not diminish the rate of the rise of blood pressure without (12 vs 14, respectively) or with proteinuria (9 vs 11), but fetal haemodynamic disturbances as assessed by Doppler equipment (1/44 vs 6/45 women studied, P= 0.05) and need for treatment in neonatal intensive care unit (10 vs 21, P= 0.04) were more rare in ASA group. ASA tended to increase the birthweight of the newborn (3348 ± 707 g vs 3170 ± 665 g, mean ± SD, P= 0.07), but two perinatal deaths occurred in ASA group. ASA prolonged the bleeding time of the mother (435 s, 210–998 s (geometric mean, range) vs 349 s, 210–690 s, P= 0.02), but caused no extra blood loss during delivery, nor affected neonatal hemostasis. In a subgroup of mothers (ASA, n = 10; placebo, n = 8), ASA inhibited more than 90% of platelet TxA2-production, and caused a 65 to 80% decrease in the urinary excretion of TxA2 metabolites, but no decrease in the urinary excretion of PGI2 metabolites. Conclusions ASA did not prevent the rise of maternal hypertension, but improved fetal haemodynamic performance and reduced the need of intensive neonatal care. It inhibited strongly maternal thromboxane A2 but not PGI2 production and thus shifted the balance between PGI2/TxA2 to the dominance of the vasodilatory, anti-aggregatory side." @default.
• W2095470682 created "2016-06-24" @default.
• W2095470682 creator A5001051995 @default.
• W2095470682 creator A5008102922 @default.
• W2095470682 creator A5009892971 @default.
• W2095470682 creator A5043494214 @default.
• W2095470682 creator A5091422048 @default.
• W2095470682 date "1993-09-01" @default.
• W2095470682 modified "2023-09-23" @default.
• W2095470682 title "Low dose aspirin in hypertensive pregnant women: effect on pregnancy outcome and prostacyclin-thromboxane balance in mother and newborn" @default.
• W2095470682 cites W1971445480 @default.
• W2095470682 cites W1973459042 @default.
• W2095470682 cites W1985001641 @default.
• W2095470682 cites W1985122146 @default.
• W2095470682 cites W1989987972 @default.
• W2095470682 cites W200459668 @default.
• W2095470682 cites W2021855226 @default.
• W2095470682 cites W2021879241 @default.
• W2095470682 cites W2022461235 @default.
• W2095470682 cites W2037337534 @default.
• W2095470682 cites W2042457377 @default.
• W2095470682 cites W2048260363 @default.
• W2095470682 cites W2049556573 @default.
• W2095470682 cites W2052315898 @default.
• W2095470682 cites W2065342543 @default.
• W2095470682 cites W2082285132 @default.
• W2095470682 cites W2103222523 @default.
• W2095470682 cites W2340870097 @default.
• W2095470682 doi "https://doi.org/10.1111/j.1471-0528.1993.tb14304.x" @default.
• W2095470682 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8217999" @default.
• W2095470682 hasPublicationYear "1993" @default.
• W2095470682 type Work @default.
• W2095470682 sameAs 2095470682 @default.
• W2095470682 citedByCount "91" @default.
• W2095470682 countsByYear W20954706822014 @default.
• W2095470682 countsByYear W20954706822015 @default.
• W2095470682 countsByYear W20954706822016 @default.
• W2095470682 countsByYear W20954706822017 @default.
• W2095470682 countsByYear W20954706822018 @default.
• W2095470682 countsByYear W20954706822019 @default.
• W2095470682 countsByYear W20954706822020 @default.
• W2095470682 countsByYear W20954706822021 @default.
• W2095470682 countsByYear W20954706822022 @default.
• W2095470682 countsByYear W20954706822023 @default.
• W2095470682 crossrefType "journal-article" @default.
• W2095470682 hasAuthorship W2095470682A5001051995 @default.
• W2095470682 hasAuthorship W2095470682A5008102922 @default.
• W2095470682 hasAuthorship W2095470682A5009892971 @default.
• W2095470682 hasAuthorship W2095470682A5043494214 @default.
• W2095470682 hasAuthorship W2095470682A5091422048 @default.
• W2095470682 hasConcept C126322002 @default.
• W2095470682 hasConcept C131872663 @default.
• W2095470682 hasConcept C142724271 @default.
• W2095470682 hasConcept C204787440 @default.
• W2095470682 hasConcept C27081682 @default.
• W2095470682 hasConcept C2777218350 @default.
• W2095470682 hasConcept C2777628954 @default.
• W2095470682 hasConcept C2779234561 @default.
• W2095470682 hasConcept C2781128415 @default.
• W2095470682 hasConcept C29456083 @default.
• W2095470682 hasConcept C46973012 @default.
• W2095470682 hasConcept C54355233 @default.
• W2095470682 hasConcept C71924100 @default.
• W2095470682 hasConcept C86803240 @default.
• W2095470682 hasConceptScore W2095470682C126322002 @default.
• W2095470682 hasConceptScore W2095470682C131872663 @default.
• W2095470682 hasConceptScore W2095470682C142724271 @default.
• W2095470682 hasConceptScore W2095470682C204787440 @default.
• W2095470682 hasConceptScore W2095470682C27081682 @default.
• W2095470682 hasConceptScore W2095470682C2777218350 @default.
• W2095470682 hasConceptScore W2095470682C2777628954 @default.
• W2095470682 hasConceptScore W2095470682C2779234561 @default.
• W2095470682 hasConceptScore W2095470682C2781128415 @default.
• W2095470682 hasConceptScore W2095470682C29456083 @default.
• W2095470682 hasConceptScore W2095470682C46973012 @default.
• W2095470682 hasConceptScore W2095470682C54355233 @default.
• W2095470682 hasConceptScore W2095470682C71924100 @default.
• W2095470682 hasConceptScore W2095470682C86803240 @default.
• W2095470682 hasIssue "9" @default.
• W2095470682 hasLocation W20954706821 @default.
• W2095470682 hasLocation W20954706822 @default.
• W2095470682 hasOpenAccess W2095470682 @default.
• W2095470682 hasPrimaryLocation W20954706821 @default.
• W2095470682 hasRelatedWork W2002269694 @default.
• W2095470682 hasRelatedWork W2018480122 @default.
• W2095470682 hasRelatedWork W2902115400 @default.
• W2095470682 hasRelatedWork W2947020781 @default.
• W2095470682 hasRelatedWork W3121012523 @default.
• W2095470682 hasRelatedWork W3210091886 @default.
• W2095470682 hasRelatedWork W4200592600 @default.
• W2095470682 hasRelatedWork W4307815470 @default.
• W2095470682 hasRelatedWork W4316927578 @default.
• W2095470682 hasRelatedWork W212640414 @default.
• W2095470682 hasVolume "100" @default.
• W2095470682 isParatext "false" @default.
• W2095470682 isRetracted "false" @default.
• W2095470682 magId "2095470682" @default.
• W2095470682 workType "article" @default.